APR supports international education on Diabetic Foot

APR Applied Pharma Research s.a. confirms its commitment as a community sponsor for the organization of the International Diabetic Foot Course, organized by Prof. Alberto Piaggesi, that will take place at the end of September at the University Hospital of Pisa.

This course, which combines lectures from different specialists and individual training, aims at supporting an international educational network by discussing and implementing solutions to the challenges related to treatment and prevention of diabetic foot ulcers.

Diabetic foot ulcers represent indeed a serious and potentially highly debilitating condition for diabetic patients, with noteworthy impacts on patients’ lives and cost of cure.

APR, always focused on the development of innovative healthcare products addressing patients’ unmet needs, thanks to its proprietary and patented technology TEHCLO®, has developed Nexodyn, a novel treatment for the effective management of a variety of wound conditions.

Nexodyn is an acidOxidizing spray solution, characterized by pH<3, RedOx >1000mV and stabilized Hypochlorous Acid (>95% of free chlorine species) – intended for use in the debridement, cleansing, irrigation and moistening of acute and chronic wounds, ulcers, cuts, abrasions, burns and other lesions.

A wide array of non-clinical experiments and clinical observations suggest Nexodyn to act as a valid support to the activation of the physiological micro-environmental processes that sustain the wound healing continuum, in presence of a favorable safety and tolerability profile.

As part of APR’s plan on educational support, other two educational events have been recently sponsored:

  • The Consensus Day of the International Working Group of the Diabetic Foot (IWGDF), a well-established international working group, which has obtained unconditioned sponsoring to update the Practical Guidelines on the Management and the Prevention of the Diabetic Foot, which are also reflected in recent international publications aimed at disseminating the most recent recommendations for an optimized DFU management.
  • The Antimicrobial Stewardship in Wound, a meeting gathering worldwide renown experts discussing on the topic: “Combatting Antimicrobial Misuse in Wound Care” and aiming at strengthening the knowledge of healthcare stakeholders by setting the basis for the identification of best practices in prevention, diagnosis and treatment of wound infection, thus reducing the (mis)use of systemic and local antibiotics. Presentations held during the Stewardship are visible at http://ewma.org/index.php?id=3079.
2015-09-25T09:47:14+00:00 Applied Pharma Research (APR)